246 related articles for article (PubMed ID: 9010834)
1. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
2. Plasma aldosterone response to metoclopramide in patients with Cushing's disease.
Zacharieva S; Stoeva I; Matrozov P; Andonova K
Exp Clin Endocrinol; 1993; 101(3):138-43. PubMed ID: 8223981
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy.
Jungmann E; Haak T; Althoff PH; Fassbinder W; Schöffling K
Arzneimittelforschung; 1988 Feb; 38(2):296-300. PubMed ID: 3285838
[TBL] [Abstract][Full Text] [Related]
5. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion.
Demura R; Naruse M; Isawa M; Onoda N; Naruse K; Yamakado M; Demura H
Endocrinol Jpn; 1992 Apr; 39(2):169-76. PubMed ID: 1396349
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
[TBL] [Abstract][Full Text] [Related]
7. [Macroprolactinoma resistant to bromocriptine].
López-Espinosa E; Ayala AR; Grimaldo J; Kunhardt J; Villanueva C
Arch Invest Med (Mex); 1989; 20(1):1-8. PubMed ID: 2669670
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of prolactinoma with a new dopamine agonist].
Svoboda T; Luger A; Knosp E; Geyer G
Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
[TBL] [Abstract][Full Text] [Related]
9. Serum aldosterone response to metoclopramide in normal subjects and acromegalic patients.
Zacharieva S; Stoeva I; Matrozov P; Andonova K
Exp Clin Endocrinol; 1990 Aug; 95(3):331-8. PubMed ID: 2245821
[TBL] [Abstract][Full Text] [Related]
10. Giant invasive prolactinoma: a case report and review of nine further cases.
Davis JR; Sheppard MC; Heath DA
Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
[TBL] [Abstract][Full Text] [Related]
11. Evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.
Jungmann E; Schwedes U; Althoff PH; Rosak C; Schöffling K
Horm Metab Res; 1986 Oct; 18(10):704-5. PubMed ID: 3781476
[TBL] [Abstract][Full Text] [Related]
12. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
Nickelsen T; Jungmann E; Althoff P; Schumm-Draeger PM; Usadel KH
Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
[TBL] [Abstract][Full Text] [Related]
13. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
[TBL] [Abstract][Full Text] [Related]
14. The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman.
Verhelst J; Beckers A; Abs R
Fertil Steril; 1995 Nov; 64(5):969-71. PubMed ID: 7589643
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of hypothalamic dopaminergic function in patients with pituitary prolactinoma.
Xia P; Shi YF
Proc Chin Acad Med Sci Peking Union Med Coll; 1989; 4(3):121-5. PubMed ID: 2594732
[TBL] [Abstract][Full Text] [Related]
16. [Immediate efficacy of bromocriptine (BrC)-LAR in the treatment of macroprolactinomas: apropos of a case].
García Calzado MC; Ruiz Buendía A
Rev Clin Esp; 1992 Jun; 191(2):112-3. PubMed ID: 1502384
[No Abstract] [Full Text] [Related]
17. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
18. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of metoclopramide for endocrine versus renal effects of dopamine in normal humans.
Blumberg AL; Dubb JW; Allison NL; Aldins Z; Ramey K; Stote RM
J Cardiovasc Pharmacol; 1988 Feb; 11(2):181-6. PubMed ID: 2452312
[TBL] [Abstract][Full Text] [Related]
20. Effects of bromocriptine on renin, aldosterone, and prolactin responses to posture and metoclopramide in idiopathic edema: possible therapeutic approach.
Sowers J; Catania R; Paris J; Tuck M
J Clin Endocrinol Metab; 1982 Mar; 54(3):510-6. PubMed ID: 7035482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
